You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).

Figure INF-6:  Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (iv) All injecting drug users – map of EU, 2003 to 2004

Figure INF-06 part iv

Notes:

Figures in [brackets] are local data. Colour indicates midpoint of national data, or if not available, of local data.

Data for Italy and Portugal include non-injectors and are likely to underestimate prevalence in injectors

* Data in part or totally before 2003 (Czech Republic 2002-03; Estonia 2002; Latvia 2001; Lithuania 2000).

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national focal points. For primary sources, study details and data before 2003, see Table INF-11.